Picture of SMS Lifesciences India logo

SMSLIFE SMS Lifesciences India Share Price

0.000.00%
in flag iconLast trade - 00:00
HealthcareAdventurousMicro CapNeutral

Momentum

Relative Strength (%)
1m-0.58%
3m+10.08%
6m+11.51%
1yr-3.72%
Volume Change (%)
10d/3m-55.21%
Price vs... (%)
52w High-15.08%
50d MA+4.7%
200d MA+20.1%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital4.1%
Return on Equity2.97%
Operating Margin3.43%

Financial Summary

Year End 31st MarUnit201920202021202220232024E2025ECAGR / Avg
Total RevenueIN₹m3,778.522,607.812,655.923,497.453,155.6n/an/a7.73%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%+176.06-43.3+33.43+41.73-48.7n/an/an/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of SMS Lifesciences India EPS forecast chart

Profile Summary

SMS Lifesciences India Limited is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph.Eur / IP, Famotidine USP / Ph.Eur / IP, Sildenafil Citrate USP / Ph.Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph.Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private limited.

Directors

Last Annual
March 31st, 2023
Last Interim
December 31st, 2023
Incorporated
May 31st, 2006
Public Since
August 17th, 2017
No. of Shareholders
8,351
No. of Employees
567
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
in flag iconNational Stock Exchange of India
Shares in Issue
3,023,287

SMSLIFE Share Price Performance

Upcoming Events for SMSLIFE

Q4 2024 SMS Lifesciences India Ltd Earnings Release

Q1 2025 SMS Lifesciences India Ltd Earnings Release

SMS Lifesciences India Ltd Annual Shareholders Meeting

Similar to SMSLIFE

Picture of Aarey Drugs and Pharmaceuticals logo

Aarey Drugs and Pharmaceuticals

in flag iconNational Stock Exchange of India

Picture of Aarti Drugs logo

Aarti Drugs

in flag iconNational Stock Exchange of India

Picture of Aarti Pharmalabs logo

Aarti Pharmalabs

in flag iconNational Stock Exchange of India

Picture of Abbott India logo

Abbott India

in flag iconNational Stock Exchange of India

Picture of Accent Microcell logo

Accent Microcell

in flag iconNational Stock Exchange of India

FAQ